1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border
Article first published online: 22 DEC 2005
DOI: 10.1111/j.1365-2036.2006.02755.x
Additional Information
How to Cite
CARDENAS, V. M., GRAHAM, D. Y., EL-ZIMAITY, H. M. T., OPEKUN, A. R., CAMPOS, A., CHAVEZ, A. and GUERRERO, L. (2006), Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Alimentary Pharmacology & Therapeutics, 23: 295–301. doi: 10.1111/j.1365-2036.2006.02755.x
Publication History
- Issue published online: 22 DEC 2005
- Article first published online: 22 DEC 2005
- Publication data Submitted 5 August 2005 First decision 24 August 2005 Resubmitted 25 September 2005 Resubmitted 1 November 2005 Accepted 2 November 2005
- Abstract
- Article
- References
- Cited By
Summary
Background Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure.
Aim To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study population.
Methods Adults from Ciudad Juarez with H. pylori infections identified by culture or histology received rabeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g, each b.d. for 7 days. Outcome was assessed by 13C-urea breath test carried out 4+ weeks after treatment.
Results A total of 111 patients were enrolled and evaluated by urea breath test; 102 completed the full 7 days therapy. Two deviated from protocol, and five stopped because of adverse events. The cure rate (intention-to-treat) was 85% (95% CI: 78–91%); the per-protocol cure rate was 85% (95% CI: 78–91%). Side-effects were not serious and only 6.6% of those with adverse events stopped medication. Only three isolates were clarithromycin-resistant and none was cured. Compliance explained most of the successes.
Conclusions In the study population a 7-day rabeprazole triple eradication therapy was both effective and well-tolerated. Clarithromycin resistance was uncommon. We observed a slightly better outcome but consistent with results from recent large studies in US populations.